Chabiotech Co Ltd

Chabiotech's capital structure is heavily leveraged, with a debt-to-equity ratio of 3.07, indicating a significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.67, which is below 1, suggesting that it may struggle to meet its short-term obligations. The company's negative operating and free cash flows further underscore its liquidity challenges, with operating cash flow at -72.5 billion KRW and free cash flow at -242.6 billion KRW. In terms of profitability, Chabiotech is currently unprofitable, with a net loss of 109.9 billion KRW and an operating loss of 99.6 billion KRW. The company's return on equity is -36.07%, and its return on assets is -4.31%, both of which are significantly below the industry median for healthcare facilities and services. These metrics indicate that the company is not generating returns that meet the expectations of its equity and asset investors. Chabiotech's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks, particularly in its primary operating region. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The analyst estimates for the last actual revenue were 488.6 billion KRW, which is lower than the reported revenue of 1.27 trillion KRW. This discrepancy may indicate a need for further investigation into the company's revenue recognition practices or potential one-time gains. Chabiotech faces several risk factors, including its high debt load and negative cash flows, which could lead to liquidity constraints and potential default. The company's dilution risk is currently low, but its high debt-to-equity ratio and negative net cash position suggest that it may need to issue additional equity in the future to service its debt obligations. The company has not disclosed any recent dilutive events, but its financial position may necessitate such actions in the near term. Recent events, as reflected in the financial data, include a significant net loss and a decline in operating income, which may be indicative of operational inefficiencies or market challenges. The company has not disclosed any recent filings or transcripts that provide further insight into its strategic direction or operational performance.